Latest Nasdaq News

Veris Limited has expanded its relationship with Hexagon’s Octave by becoming the authorised geospatial software distributor across Australia and New Zealand, aiming to generate an initial $1.2 million in annual recurring revenue.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.

Metallium Limited has marked a pivotal quarter with over 40 Flash Joule Heating campaigns completed and a strategic capital raise boosting cash reserves to A$82 million. The company is gearing up for multi-reactor operation at its Texas campus, underpinned by long-term agreements with Indium Corporation and Glencore.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

Jindalee Lithium Limited's US subsidiary, HiTech Minerals, has signed a binding agreement with Constellation Acquisition Corp I to form US Elemental Inc., a NASDAQ-listed company holding the McDermitt Lithium Project. The transaction values the new entity at approximately US$571 million enterprise value, with Jindalee retaining majority ownership.

Red Mountain Mining Ltd is set to recommence exploration at its US antimony projects following winter, supported by US government initiatives and strengthened by a new advisory appointment. The company plans systematic geological mapping and sampling across multiple projects, aiming to advance towards drill testing and resource definition.

American Uranium Limited (ASX:AMU) has secured A$2.64 million through a placement after upgrading its Lo Herma uranium resource to 9.45 million pounds eU3O8 with improved grade. The company also plans a non-renounceable rights entitlement offer to raise up to A$2.58 million, supporting further drilling and technical studies ahead of a Q3 2026 Scoping Study.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Resolution Minerals Ltd has secured FAST-41 status for its Antimony Ridge project in Idaho, a designation expected to accelerate permitting and development of this critical minerals asset. The move supports the company's integrated U.S. strategy for antimony, tungsten, and gold, enhancing investor visibility and strategic engagement.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.